|
|
Vaccine Detail
|
NDV-VF/S vaccine |
| Vaccine Information |
- Vaccine Name: NDV-VF/S vaccine
- Target Pathogen: SARS-CoV
- Target Disease: Severe Acute Respiratory Syndrome (SARS)
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Monkey
- Antigen: Full-length 1,255-aa SARS-CoV S protein (DiNapoli et al., 2007)
- Immunization Route: intranasal immunization
|
| Host Response |
|
Monkey Response
- Host Strain: African Green Monkey
- Vaccination Protocol: Monkeys were vaccinated with 107 pfu of the recombinant virus days 0 and 28 (the two-dose groups) or on day 0 only (the one-dose group). (DiNapoli et al., 2007)
- Immune Response: Induced neutralizing antibodies, Produced S-specific antubodies, Increase in CD8+ T cells creating IFN-γ and TNF-α1 (DiNapoli et al., 2007)
- Challenge Protocol: 28 days after the second dose, they were challenged by the i.n. and i.t. routes with SARS-CoV at a tissue culture 50% infectious dose (TCID50) of 10^6 per site. (DiNapoli et al., 2007)
- Efficacy: Protected (DiNapoli et al., 2007)
- Description: Immunization with NDV-VF/S resulted in a 5-fold and 61-fold reduction in nasal turbinate and tracheal SARS-CoV titers, respectively, compared with the control animals. (DiNapoli et al., 2007)
|
| References |
DiNapoli et al., 2007: DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(23); 9788-9793. [PubMed: 17535926].
|
|
